Primary Site >> Colorectal Cancer
Gene >> TNFRSF9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. PMID: 10841829 Ref: Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. PMID: 10899826 |
Ref: Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. PMID: 15054868 Ref: Assessment expression of the adhesion molecules, CD134 and CD137, in patients with colorectal cancer by flow cytometry. PMID: 15638367 |
Ref: Expression of CD137 and CD137 ligand in colorectal cancer patients. PMID: 16596186 |
Ref: Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. PMID: 17460060 Ref: Immunotherapy and immunoescape in colorectal cancer. PMID: 17990348 |
Ref: Analysis of CD137 and CD137L expression in human primary tumor tissues. PMID: 18461674 |
Ref: CD1d-based combination therapy eradicates established tumors in mice. PMID: 19620318 |
Ref: Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. PMID: 20179677 Ref: Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. PMID: 20336294 Ref: Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells. PMID: 20607237 |
Ref: Intratumoral injection of interferon-alpha and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. PMID: 20309938 Ref: Determination of the activity of CD134 (OX-40) and CD137 (4-1BB) adhesive molecules by means of flow cytometry in patients with colorectal cancer metastases to the liver. PMID: 22166715 Ref: Assessment of activity of an adhesion molecule CD134 and CD137 in colorectal cancer patients. PMID: 22343199 |
Ref: The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. PMID: 22719018 |
Ref: PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody. PMID: 24829750 |
Ref: Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice. PMID: 24788789 Ref: Targeting CD137 enhances the efficacy of cetuximab. PMID: 24837434 Ref: Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells. PMID: 24892449 Ref: Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers. PMID: 24934848 |
Ref: Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state. PMID: 25363339 |
Ref: Immunotherapy of Colorectal Cancer. PMID: 27259331 Ref: Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. PMID: 27550452 |
Ref: Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. PMID: 28838649 Ref: Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer. PMID: 29179214 |
Ref: Deregulated Mucosal Immune Surveillance through Gut-Associated Regulatory T Cells and PD-1(+) T Cells in Human Colorectal Cancer. PMID: 29581358 |